In News:

The Indian government intensified its oversight of the pharmaceutical market following a surge in the availability of Glucagon-like peptide-1 (GLP-1) receptor agonists. Originally expensive, patented drugs, the recent expiration of key patents (like Semaglutide) has led to a flood of affordable generic versions. While this democratizes treatment for chronic conditions, it has also triggered a "quiet frenzy" of off-label use for rapid weight loss, prompting the Central Drugs Standard Control Organisation (CDSCO) to conduct nationwide inspections across 49 businesses.

What are GLP-1 Drugs?

GLP-1 receptor agonists are a class of medications that mimic a natural hormone produced in the intestines.

• Mechanism of Action:
  • Insulin Stimulation: They signal the pancreas to release insulin and suppress glucagon in response to rising blood glucose levels.
  • Appetite Regulation: They target the brain’s hypothalamus to regulate satiety (the feeling of fullness).
  • Gastric Emptying: They slow down the movement of food through the stomach, prolonging the sensation of satiety.
• Primary Indications: Developed originally by global giants like Novo Nordisk and Eli Lilly, these are FDA and CDSCO-approved for Type 2 Diabetes mellitus and the medical management of chronic obesity.
• Key Molecules: Semaglutide (oral/injectable), Liraglutide, Tirzepatide, and Dulaglutide.

The "Generic Boom" and Economic Impact

The Indian market for obesity drugs is projected to grow from ?1,500 crore to ?8,000 crore by 2030.

• Price Crash: Leading Indian firms have slashed prices significantlysome by over 50%to as low as ?3,999 per month.
• Market Dynamics: The expiration of patent protection has allowed domestic manufacturers to launch biosimilars and generics, making India a global hub for these "lifestyle-altering" medications.

Regulatory Framework and Government Response

Due to the high risk of misuse, the Government of India has classified these as Preion-Only Medicines.

• Authorized Prescribers: To prevent indiscriminate use, only Endocrinologists, Internal Medicine Specialists, and Cardiologists are authorized to prescribe these drugs.
• Central and State Coordination: The Drug Controller General of India (DCGI), in collaboration with State Drug Controllers, has implemented a three-pronged strategy:
  1. Nationwide Audits: Inspections of online pharmacy warehouses, drug wholesalers, and wellness clinics to check for sales without valid preions.
  2. Ban on Surrogate Advertising: On March 10, 2026, the CDSCO issued a comprehensive advisory prohibiting indirect promotion and misleading advertisements that frame these as "quick-fix" cosmetic solutions.
  3. Post-Marketing Surveillance: The Indian Pharmacopoeia Commission (IPC) has been tasked with compiling bi-monthly reports on "Adverse Events" to monitor long-term safety.

Public Health Risks: Misuse and Side Effects

The trend of viewing GLP-1 drugs as "lifestyle products" rather than clinical medication has raised alarms among the medical fraternity (including the Indian Medical Association).

• Common Side Effects: Nausea, vomiting, diarrhea, and constipation.
• Severe Complications: Rare but serious risks include pancreatitis, kidney injury, gallbladder disease, and delayed gastric emptying (gastroparesis).
• "Ozempic Face": Rapid weight loss leading to facial fat depletion and skin sagging.
• Rebound Effect: Without supervised lifestyle changes, patients often face "rebound weight gain" immediately after discontinuation.